Patent US5639473A successfully refreshed from Google Patents.
US5639473A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for the preparation of nucleic acids for in vivo delivery
Assignee: Abraxis Bioscience LLC
•
Filing: 1995-06-07
•
Granted: 1997-06-17
•
Expires: 2015-06-07
Abstract
Abstract In accordance with the present invention, there are provided compositions useful for the in vivo delivery of a biologic, wherein the biologic is associated with a polymeric shell formulated from a biocompatible material. The biologic can be associated with the polymeric shell itself, and/or the biologic, optionally suspended/dispersed in a biocompatible dispersing agent, can be encased by the polymeric shell. In another aspect, the biologic associated with polymeric shell is administered to a subject, optionally dispersed in a suitable biocompatible liquid.
Inventors
- 👤 Mark W. Grinstaff
- 👤 Patrick Soon-Shiong
- 👤 Michael Wong
- 👤 Paul A. Sandford
- 👤 Kenneth S. Suslick
- 👤 Neil P. Desai
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 23:10
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0026; A23; A23L; A23L33/00; A23L33/40; A61K47/00; A61K47/50; A61K47/69; A61K47/6921; A61K47/6925; A61K47/6927; A61K49/00; A61K49/06; A61K49/08; A61K49/10; A61K49/12; A61K49/126; A61K49/18; A61K49/1818; A61K49/1821; A61K49/1824; A61K49/1827; A61K49/1851; A61K49/1863; A61K49/22; A61K49/222; A61K49/223; A61K49/226; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5052; A61K9/51; A61K9/5107; A61K9/513; A61K9/5138; A61K9/5146; A61K9/5161; A61K9/5169; B; B82; B82Y; B82Y5/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
83 words
A method for the preparation of articles for in vivo delivery of nucleic acid constructs, said method comprising subjecting aqueous medium containing biocompatible material capable of being crosslinked by disulfide bonds and nucleic acid construct to high intensity ultrasound conditions for a time sufficient to promote crosslinking of said biocompatible material by disulfide bonds; wherein said nucleic acid construct is substantially completely contained within a polymeric shell, and wherein the largest cross-sectional dimension of said shell is no greater than about 10 microns.
Claim 2
Independent Claim
83 words
A method for the preparation of articles for in vivo delivery of nucleic acid constructs, said method comprising subjecting aqueous medium containing biocompatible material capable of being crosslinked by disulfide bonds and nucleic acid construct to high intensity ultrasound conditions for a time sufficient to promote crosslinking of said biocompatible material by disulfide bonds; wherein said nucleic acid construct is substantially completely contained within a polymeric shell, and wherein the largest cross-sectional dimension of said shell is no greater than about 10 microns.
Claim 3
Dependent Claim
37 words
The method according to claim 1, wherein said biocompatible material is a naturally occurring polymer, a synthetic polymer, or a combination thereof, wherein said polymer, prior to crosslinking, has covalently attached thereto sulfhydryl groups or disulfide linkages.
Claim 4
Dependent Claim
51 words
The method according to claim 2, wherein said naturally occurring polymer is selected from proteins containing sulfhydryl groups and/or disulfide groups, polypeptides containing sulfhydryl groups and/or disulfide groups, lipids containing sulfhydryl groups and/or disulfide groups, polynucleic acids containing sulfhydryl groups and/or disulfide groups, or polysaccharides containing sulfhydryl groups and/or disulfide groups.
Claim 5
Dependent Claim
30 words
The method according to claim 3, wherein said protein is selected from hemoglobin, myoglobin, albumin, insulin, lysozyme, immunoglobulins, α-2-macroglobulin, fibronectin, vitronectin, fibrinogen, or combinations of any two or more thereof.
Claim 6
Dependent Claim
11 words
The method according to claim 4, wherein said protein is albumin.
Claim 7
Dependent Claim
11 words
The method according to claim 4, wherein said protein is hemoglobin.
Claim 8
Dependent Claim
16 words
The method according to claim 4, wherein said protein is a combination of albumin and hemoglobin.
Claim 9
Dependent Claim
55 words
The method according to claim 3, wherein said polysaccharides are selected from alginate, high M-content alginates, polymannuronic acid, polymannuronates, hyaluronic acid, hyaluronate, heparin, dextran, chitosan, chitin, cellulose, starch, glycogen, guar gum, locust bean gum, dextran, levan, inulin, cyclodextrin, agarose, xanthan gum, carrageenan, heparin, pectin, gellan gum, scleroglucan, or combinations of any two or more thereof.
Claim 10
Dependent Claim
115 words
The method according to claim 2, wherein said synthetic polymer is selected from synthetic polyamino acids containing cysteine residues and/or disulfide groups, synthetic polypeptides containing sulfhydryl groups and/or disulfide groups, polyvinyl alcohol modified to contain free sulfhydryl groups and/or disulfide groups, polyhydroxyethyl methacrylate modified to contain free sulfhydryl groups and/or disulfide groups, polyacrylic acid modified to contain free sulfhydryl groups and/or disulfide groups, polyethyloxazoline modified to contain free sulfhydryl groups and/or disulfide groups, polyacrylamide modified to contain free sulfhydryl groups and/or disulfide groups, polyvinyl pyrrolidinone modified to contain free sulfhydryl groups and/or disulfide groups, polyalkylene glycols modified to contain free sulfhydryl groups and/or disulfide groups, as well as mixtures of any two or more thereof.
Claim 11
Dependent Claim
56 words
The method according to claim 1, wherein said polymeric shell is modified by a suitable agent, wherein said suitable agent is selected from a synthetic polymer, phospholipid, a protein, a polysaccharide, a surface active agent, a chemical modifying agent, or combination thereof, wherein said agent is associated with said polymeric shell through an optional covalent linkage.
Claim 12
Dependent Claim
26 words
The method according to claim 10, wherein said synthetic polymer is selected from polyalkylene glycols, polyvinyl alcohol, polyhydroxyethyl methacrylate, polyacrylic acid, polyethyloxazoline, polyacrylamide, or polyvinyl pyrrolidinone.
Claim 13
Dependent Claim
23 words
The method according to claim 10, wherein said phospholipid is selected from phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI), or sphingomyelin.
Claim 14
Dependent Claim
16 words
The method according to claim 10, wherein said protein is selected from an enzyme or antibody.
Claim 15
Dependent Claim
21 words
The method according to claim 10, wherein said polysaccharide is selected from starch, cellulose, dextrans, alginates, chitosan, pectin, or hyaluronic acid.
Claim 16
Dependent Claim
23 words
The method according to claim 10, wherein said chemical modifying agent is selected from pyridoxal 5'-phosphate, derivatives of pyridoxal, dialdehydes, or diaspirin esters.
Claim 17
Dependent Claim
29 words
The method according to claim 1, wherein said nucleic acid constructs are selected from IGF-1 encoding sequence, Factor VIII encoding sequence, Factor IX encoding sequence, or antisense nucleotide sequences.
Claim 18
Dependent Claim
16 words
The method according to claim 16, wherein said nucleic acid construct is an IGF-1 encoding sequence.
Claim 19
Dependent Claim
17 words
The method according to claim 16, wherein said nucleic acid construct is a Factor VIII encoding sequence.
Claim 20
Dependent Claim
17 words
The method according to claim 16, wherein said nucleic acid construct is a Factor IX encoding sequence.
Claim 21
Dependent Claim
16 words
The method according to claim 16, wherein said nucleic acid construct is an antisense nucleotide sequence.
Claim 22
Dependent Claim
23 words
The method according to claim 1, wherein said nucleic acid construct within said shell is dissolved or suspended in a biocompatible dispersing agent.
Claim 23
Dependent Claim
89 words
The method according to claim 21, wherein said biocompatible dispersing agent is selected from soybean oil, coconut oil, olive oil, safflower oil, cotton seed oil, aliphatic, cycloaliphatic or aromatic hydrocarbons having 4-30 carbon atoms, aliphatic or aromatic alcohols having 2-30 carbon atoms, aliphatic or aromatic esters having 2-30 carbon atoms, alkyl, aryl, or cyclic ethers having 2-30 carbon atoms, alkyl or aryl halides having 1-30 carbon atoms, optionally having more than one halogen substituent, ketones having 3-30 carbon atoms, polyalkylene glycol, or combinations of any two or more thereof.
Claim 24
Dependent Claim
15 words
The method according to claim 21, wherein said dispersing agent comprises a volatile dispersing agent.
Claim 25
Dependent Claim
30 words
The method according to claim 23, wherein said volatile dispersing agent is selected from benzene, toluene, hexane, ethyl ether, dichloromethane, ethyl acetate, or combinations of any two or more thereof.
Claim 26
Dependent Claim
66 words
The method according to claim 1, wherein said polymeric shell containing said nucleic acid construct is suspended in a biocompatible medium, and wherein said biocompatible medium is selected from water, buffered aqueous media, saline, buffered saline, solutions of amino acids, solutions of proteins, solutions of sugars, solutions of vitamins, solutions of carbohydrates, solutions of synthetic polymers, lipid-containing emulsions, or combinations of any two or more thereof.
Claim 27
Dependent Claim
52 words
A method for the delivery of a nucleic acid construct to a subject in need thereof, said method comprising administering to said subject an article prepared by the method of claim 1 by oral, intravenous, subcutaneous, intraperitoneal, intraperitoneal, intrathecal, intramuscular, intracranial, inhalational, topical, transdermal, suppository (rectal), or pessary (vaginal) routes of administration.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-06-16 | 2000-12-16 | 2001-06-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-06-16 | 2004-12-16 | 2005-06-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-06-16 | 2008-12-16 | 2009-06-17 | $7700.00 | Window Closed / Lapsed |